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ABSTRACT
Activation of ribosomal RNA (rRNA) synthesis is
pivotal during cell growth and proliferation, but
its aberrant upregulation may promote tumorigen-
esis. Here, we demonstrate that the candidate on-
coprotein, LYAR, enhances ribosomal DNA (rDNA)
transcription. Our data reveal that LYAR binds the
histone-associated protein BRD2 without involve-
ment of acetyl-lysine–binding bromodomains and re-
cruits BRD2 to the rDNA promoter and transcribed re-
gions via association with upstream binding factor.
We show that BRD2 is required for the recruitment of
the MYST-type acetyltransferase KAT7 to rDNA loci,
resulting in enhanced local acetylation of histone H4.
In addition, LYAR binds a complex of BRD4 and KAT7,
which is then recruited to rDNA independently of the
BRD2-KAT7 complex to accelerate the local acety-
lation of both H4 and H3. BRD2 also helps recruit
BRD4 to rDNA. By contrast, LYAR has no effect on
rDNA methylation or the binding of RNA polymerase
I subunits to rDNA. These data suggest that LYAR
promotes the association of the BRD2-KAT7 and
BRD4-KAT7 complexes with transcription-competent
rDNA loci but not to transcriptionally silent rDNA loci,
thereby increasing rRNA synthesis by altering the lo-
cal acetylation status of histone H3 and H4.
INTRODUCTION
The ribosome is the essential cellular machinery for pro-
tein synthesis. The eukaryotic ribosome consists of a large
60S subunit and a small 40S subunit, the biogenesis of
which requires transcription of a large ribosomal RNA
precursor (47S pre-rRNA) by RNA polymerase (RNAP)
I, a 5S rRNA by RNAP III, and translation of riboso-
mal proteins from mRNAs transcribed by RNAP II (1–
6). In addition, numerous small nucleolar RNAs and non-
ribosomal proteins (called trans-acting factors) participate
in ribosome biogenesis (5,6). Among these factors, many
contribute to the synthesis of 47S pre-rRNA, which alone
constitutes ∼80% of the total transcription of proliferat-
ing cells (1,2). Because of its predominance, rDNA tran-
scription is regulated by ≥30 trans-acting factors, includ-
ing proto-oncogene products (MYC, etc.) and tumor sup-
pressors (p53, retinoblastoma, etc.) to maintain appropri-
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ate ribosome numbers in normal cells (1–3,7). Upon onco-
genic transformation of a cell, however, rRNA synthesis
is upregulated by altered function of these types of fac-
tors, e.g. owing to their dysregulated expression and/or
mutation (1). In certain tumor cells, the upregulation of
rRNA synthesis occurs via phosphorylation of upstream
binding factor (UBF), a rDNA promoter–binding protein
that mediates binding of selectivity factor 1 (SL1) to the
rDNA promoter, resulting in the recruitment of RNAP
I. The increased activity of casein kinase II or of com-
plexes formed between the mitotic cyclins and the cyclin-
dependent kinases (CDK4-cyclin D1, CDK2-cyclin E) or
the mitogen-activated protein kinase ERK (extracellular
signal–regulated kinase) is responsible for this upregula-
tion in certain cell types (1,2,7). For instance, casein ki-
nase II phosphorylates the serine-rich carboxyl-terminal
acidic tail of UBF, thereby promoting its interaction with
SL1 (8). Failure to interrupt the binding between SL1 and
UBF is another mechanism underlying the upregulation of
rDNA transcription in cancer cells, which is often caused
by inactivating mutations of the tumor-suppressor pro-
tein retinoblastoma or p53 (7,8). Another mechanism of
rDNA upregulation occurs through increased expression of
MYC along with the sequence-specific DNA-binding pro-
tein Max, which associates with CACGTG in the rDNA
promoter and activates RNAP I–dependent transcription
via recruitment of transformation/transcription domain–
associated protein that bridges between MYC and the hi-
stone acetyltransferase GCN5, resulting in local acetyla-
tion of nucleosomal histones in rDNA loci (9–11). In addi-
tion, rRNA synthesis is accelerated at the level of transcrip-
tional elongation by the actions of chromatin-remodeling
and elongation complexes including the FACT and PAF
complexes (12,13) and/or histone chaperones including nu-
cleolin (14).
LYAR, the human ortholog of the mouse nucleolar pro-
tein LYAR (Ly-1 antibody-reactive clone), is a 45-kDa pro-
tein with 379 amino acid residues including a zinc-finger
motif and three nuclear localization signals (15). LYAR is
conserved across many species, including mammals. Mouse
LYARmRNA is detectable in immature spermatocytes and
testes in early embryos and to a lesser extent in fetal liver
and thymus tissue (15–17). In adult mice, the mRNA is de-
tectable at low levels in kidney and spleen but not in other
differentiated tissues including brain; however, the mRNA
is expressed at very high levels in a number of mouse B- and
T-cell leukemia lines (15). Mouse fibroblasts overexpress-
ing mouse LYAR cDNA contribute to tumor formation in
nude mice; thus, LYAR is believed to be a nucleolar onco-
protein that regulates the growth and proliferation of cancer
cells (15). In support of this idea, LYAR is overexpressed
in human medulloblastoma, the most common brain tu-
mor in children (18), and it is also highly expressed in hu-
manmetastatic colorectal cancer cells (19).Moreover, when
overexpressed in vitro, LYAR increases the already potent
proliferative capacity of HeLa cells (human uterine cervical
cancer) and MCF cells (human breast cancer) (20).
Moreover, mouse LYAR is necessary for the expression
of the fetal globin gene via its ability to associate with pro-
tein arginine methyl transferase 5 (21), and it is indispens-
able for cell proliferation and development of female mouse
embryos in which TP53 (encoding p53) is experimentally
disrupted (16,22). Mouse LYAR also associates with nucle-
olin, a trans-acting factor involved in various stages of ri-
bosome biogenesis, and together these proteins help main-
tain the pluripotency of embryonic stem cells (23). In addi-
tion, LYAR can bind to immature ribosome particles as well
as a number of nucleolar proteins, including nucleophos-
min (also known as B23), DDX21, UBF, and treacle, which
is the product of TCOF1, the causative gene for Treacher
Collins syndrome (24–32). LYAR also participates in pre-
rRNAprocessing (20). Althoughmodulation of rRNA syn-
thesis is linked directly to differentiation of various stem-
cell types including human embryonic stem cells (33–35),
the involvement of LYAR in rRNA synthesis remains to be
determined.
To address this shortcoming, we investigated LYAR func-
tion in human cells and found that LYAR binds rDNA via
UBFand enhances pre-rRNAsynthesis via its ability tomo-
bilize the histone-associated proteins, the BRDs, to rDNA.
UBFbinds to the active nucleolar organizer region of genes,
interacts directly with RNAP I (36), and has many func-
tions during rDNA transcription, including the pause and
release of RNAP I from the promoter (37). BRD2 enhances
the recruitment of the acetyltransferase KAT7 and BRD4
to rDNA. Both BRD2 and BRD4 belong to the BET family
of proteins and contain two tandem bromodomains and an
extra-terminal domain (38). They are involved in RNAP II–
dependent transcription and are recruited to euchromatin
regions via their interaction with acetylated histones H3
and H4 (38,39). BRD2, which was originally identified as
a Ser/Thr kinase (40,41), is necessary for the acetylation of
lysine (K) residues of H4 (42), and BRD2 has histone chap-
erone activity that is required for RNAP II–dependent tran-
scription of certain genes including cyclin A (42). BRD4 is
a global regulator of p-TEFb (positive transcription elon-
gation factor b)-dependent phosphorylation of RNAP II
(43) and was recently found to be a histone acetyltrans-
ferase specific for histones H3 and H4, including H3K122
(44). Despite the roles of BRD family proteins in RNAP
II–dependent transcription, their involvement in RNAP I–
dependent transcription is unknown. On the other hand,
KAT7, a member of a family of the MYST-type histone
acetyltransferases, is required for acetylation of histones H3
and H4 depending on which co-binding partner is involved
(JADE1, etc.) and for expression of development-specific
genes in mammalian embryos (45). Our results suggest a
mechanism by which RNAP I–dependent rRNA synthesis
is regulated by LYAR, BRD proteins, and KAT7 in human
cells.
MATERIALS AND METHODS
Metabolic labeling of newly synthesized 47S/45S pre-rRNA
The incorporation of 4-thiouridine and subsequent biotiny-
lation were performed as described (46) with some modifi-
cations, noted as follows. HeLa or 293T cells in 35-mmPetri
dishes were cultured in the presence of 10 M4-thiouridine
(Sigma) for 30 min. Cells were collected with ice-cold PBS,
and total RNA was isolated with TRIzol Reagent (Invitro-
gen). For the biotinylation of 4-thiouridine–labeled RNA,
20 g of total RNA was incubated for 3 h at 25◦C with
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0.2 mg/ml biotin-coupled N-[6-(biotinamide)hexyl]-3’-(2’-
pyridyldithio)propionamide (Pierce, 1 mg/ml in dimethyl-
formamide) in 200 l of 10 mM Tris–HCl, pH 7.4, con-
taining 1 mM EDTA. An equal volume of chloroform
was added, mixed, and incubated for 5 min. The mixture
was subjected to centrifugation at 20,000 × g for 5 min,
and the biotinylated RNA was precipitated from solution
with isopropanol. After washing with 75% ethanol, each
biotinylated RNA sample was dried and dissolved in for-
mamide. For the detection of biotinylated 47S/45S pre-
rRNA, 4 g total RNA was electrophoresed on a 0.9%
agarose/formaldehyde gel in MOPS running buffer at 3.5
V/cm for 3 h. Separated RNAs were transferred to a Hy-
bond N+ membrane, which was subsequently dried, UV
crosslinked using the CX-2000 UV Crosslinker (UVP, CA,
USA) at 120mJ/cm2, soaked in 10%acetic acid, and stained
with methylene blue. Biotinylated 47/45S pre-rRNA was
detected with horseradish peroxidase (HRP)–conjugated
streptavidin using the Chemiluminescent Nucleic Acid De-
tection Module (Thermo Scientific). Signals were detected
with the LAS-4000 system. Signal intensities of RNAbands
weremeasured usingNIH ImageJ software. To ensure equal
loading, control RNA in each gel was stained using SYBR
GOLD (Invitrogen) and quantified after the detection with
the LAS-4000 system.
All other materials and methods are provided in sup-
plementary materials including the list of antibodies (Sup-
plementary Table S1) and that of DNA primers and small
interference RNAs (Supplementary Table S2) used in this
study.
RESULTS
LYAR is overexpressed in many human cancer cells
LYAR is a candidate oncoprotein (15), sowe assessed the in-
tracellular levels of LYAR or LYAR mRNA in tissues from
normal/control subjects and cancer patients. Inmany of the
tumor samples from cancer patients, including those with
colorectal carcinoma or small-cell lung carcinoma, LYAR
mRNA levels were higher than in normal tissues (Supple-
mentary Figure S1A). In tumor samples from patients with
colorectal carcinoma, LYAR mRNA levels, as determined
by GeneChip, were higher than those in normal cells from
those patients as well as in cells from healthy subjects (Sup-
plementary Figure S1B). In addition, we examined LYAR
mRNA levels in the low-metastasis colorectal cancer cell
line SW480 and the highly metastatic line SW620 in com-
parison with HeLa cells. These cell lines were established
from the primary lesion (SW480) and lymph-node metas-
tases (SW620) of a single colorectal cancer patient (47,48).
SW620 cells expressed a much higher level of both LYAR
protein and mRNA than did SW480 cells (Supplementary
Figure S1C).
LYAR associates with rDNA and increases the expression of
47S/45S pre-rRNA
We previously reported that cancer cells, such as HeLa and
MCF7, have reduced ribosome production and prolifera-
tion when the level of LYAR is low; when the level of LYAR
is elevated, however, cell proliferation increases (20). Be-
cause LYAR accelerates the processing of pre-rRNA in cul-
tured cells including HeLa cells, we postulated that LYAR
also enhances ribosome production by accelerating rRNA
synthesis in tumor cells to helpmaintain their rapid prolifer-
ation. To test this idea, we first examined the association of
LYARwith rDNA in cultured cells includingHeLa,MCF7,
and 293T cells by ChIP in combination with quantitative
PCR using primer sets specific for regions corresponding
to the rDNA loci H0, H8, H13 and H27 that had been de-
fined by O’Sullivan et al. (49) (Figure 1A and B, Supple-
mentary Figure S2A and B). We found that LYAR binds
to the promoter region (H0) and transcribed region (H8 to
H13) of rDNA but not to the intergenic spacer encompass-
ing H27 in HeLa (Figure 1B), MCF7 (Supplementary Fig-
ure S2A), and 293T cells (Supplementary Figure S2B). This
association of LYAR with rDNA was reduced upon LYAR
knockdown in HeLa (Figure 1B) and MCF7 (Supplemen-
tary Figure S2C) cells without affecting UBF binding to
rDNA, indicating that LYAR is present at the promoter and
transcribed regions of rDNA. Tominimize the effect of pre-
rRNA processing (20), we next examined a 30-min incor-
poration of 4-thiouridine in 47S/45S pre-rRNA prepared
from cells treated with one of two different short interfering
RNAs (siRNA), and showed that it was reduced to 40–60%
compared with that measured in cells treated with negative-
control RNA (ncRNA) (Figure 1C).
To examine the effects of LYAR overexpression on its
binding to rDNA and on 47S/45S pre-rRNA synthesis,
we produced a doxycycline (Dox)-inducible Flp-In T-REx
293 cell line expressing HBF (His6-biotinylation sequence-
FLAG tag)-LYAR (HBF-LYAR-TO cells). The expression
of HBF-LYAR increased gradually over time after the ad-
dition of Dox, reaching a steady state at a level 10-fold
greater than that of endogenous LYAR (Supplementary
Figure S2D). The induced HBF-LYAR localized to the nu-
cleolus, as did endogenous LYAR, based on immunocyto-
chemistry (Supplementary Figure S2E). The upregulated
expression of HBF-LYAR led to an increase in HBF-LYAR
association with the promoter and transcribed region of
rDNA (Figure 1D) and promoted the synthesis of 47S/45S
pre-rRNA compared with noninduced cells (Figure 1E). In
addition, the increased transcription of rDNA upon HBF-
LYAR overexpression was demonstrated with a luciferase
assay using the prHu3-Luc reporter gene fused in tandem
with a rDNA promoter (Figure 1F). Notably, overexpres-
sion of HBF-LYAR did not alter the DNAmethylation sta-
tus at rDNA loci, although HBF-LYAR indeed localized to
regions of activated, unmethylated rDNA, as didUBF (Fig-
ure 1G). Collectively, these data suggested that LYAR pro-
motes rDNA transcription without activating silent rDNA.
LYAR associates with a number of proteins involved in tran-
scription
To gain insight into the role of LYAR in rDNA tran-
scription, we isolated LYAR-associated proteins present in
the nucleus. Because exogenously expressed HBF-LYAR
was indistinguishable from endogenous LYAR in terms of
the elution profile of the sucrose gradient ultracentrifuga-
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Figure 1. LYAR is involved in rDNA transcription. (A) Schematic diagram of a single human rDNA genic region (rDNA repeats are separated by an
intergenic spacer). Primer sets (short bars: subregions H0, H8, H13, and H27) used for ChIP analysis are indicated along with their approximate positions
relative to the transcription start site (0 kb). (B) ChIP analysis of UBF and LYAR binding to rDNA loci in HeLa cells transfected with scRNA (control)
or siRNA specific for LYAR. Nonspecific mouse IgG or rabbit IgG was used as the antibody control. The chromatin-immunoprecipitated (ChIPed) DNA
was quantified by qPCR using the primer sets indicated in A. The graph shows the amount of ChIPed DNA (% of input). Data represent the mean± SEM
of three independent experiments. The efficiency of LYAR knockdown was assessed with immunoblotting. (C) Metabolic labeling (4-thiouridine) of newly
synthesized 47/45S pre-rRNA inHeLa cells uponLYARknockdown. TheRNAextracted for the cells treatedwith siRNA#1, siRNA#2or ncRNA specific
for LYAR (or ncRNA, control), was biotinylated and then subjected to agarose gel electrophoresis under denaturing condition and northern blotting.
Signals for 47/45S pre-rRNA were detected by chemiluminescence. 28S and 18S rRNAs were used as loading controls (stained with methylene blue).
The graph shows the relative band intensities of biotin-labeled 47/45S pre-rRNA normalized to that of 18S rRNA. Data reflect the mean ± SEM of three
independent experiments. *P< 0.05 (paired t-test).LYARmRNA levels, normalized toGAPDHmRNA, were assessed by reverse transcription-qPCR. (D)
ChIP analysis of LYAR binding to rDNA loci (H0, H8, H13, H27) in HBF-LYAR-TO cells with or without HBF-LYAR induction via Dox. Nonspecific
rabbit IgGwas used as the antibody control. The graph shows the amount of ChIPedDNA (% of input). Data reflect the mean± SEMof three independent
experiments. (E) Metabolic labeling (4-thiouridine) of newly synthesized 47/45S pre-rRNA in HBF-LYAR-TO cells with or without Dox treatment. The
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tion of the nuclear extract (Supplementary Figure S3A),
we prepared a nuclear fraction containing UBF (Nuc in
Supplementary Figure S3B) from HBF-LYAR-TO cells
and isolated HBF-LYAR-associated complexes from the
Nuc fraction with a two-step purification using His and
FLAG tags after RNase A treatment (Figure 2A), which
did not affect the interaction between LYAR and nucleolin
(Supplementary Figure S3C) as reported (23). The puri-
fied HBF-LYAR-associated complexes were separated by
SDS-PAGE. The gel was then cut into four pieces, each
of which was subjected to in-gel digestion with trypsin
and endopeptidase Lys-C. The resulting peptides were an-
alyzed with a nanoscale liquid chromatography–coupled
tandem mass spectrometry (LC-MS/MS) system (50,51).
These proteomic analyses assigned 148 proteins in to-
tal, including those known to associate with LYAR, i.e.,
nucleophosmin/B23, nucleolin, DDX21, and treacle (Table
1, Supplementary Tables S3 and S4). Among those, seven
proteins, namely SSRP1, SPT16, BRD4, BRD2, SPT5,
CTR9 and treacle, were also detected by immunoblotting
(Figure 2B). Although UBF was identified only occasion-
ally during our MS analyses (not shown in Supplemen-
tary Tables S3 and S4, and Table 1), it was detected un-
ambiguously by immunoblotting (Figure 2B). In part, this
may have been a consequence of the lower sensitivity of
the MS-based method compared with immunoblotting and
partly because of the tight binding of UBF to rDNA, which
results in low extraction efficiency. As a negative control,
lamin B was not detected by MS or immunoblotting (Fig-
ure 2B). The identified proteins were classified in Gene On-
tology terms that were assigned using DAVID (http://www.
geneontology.org/). The top three most abundant proteins
had Gene Ontology terms for transcription (under Biolog-
ical process) and those related to protein-binding, poly(A)
RNA binding, and DNA binding (under Molecular func-
tion) (Supplementary Figure S3D and Supplementary Ta-
ble S5). Among the identified proteins, nine are compo-
nents of three elongation complexes involved in rDNA tran-
scription, i.e., the PAF1 complex (RTF1, CTR9, LEO1,
WDR61, PAF1) (13,52), FACT complex (SPT16, SSRP1)
(12,53,54), and DSIF complex (SPT4, SPT5) (55,56) (Ta-
ble 1). The other proteins, namely CD11B, CSK22, CSK2B,
PELP1,MAX, treacle, TOP1, TOP2 and XRCC5, also par-
ticipate in rDNA transcription (3) (Table 1). In addition, nu-
cleophosmin and nucleolin participate in rDNA transcrip-
tion as histone chaperones (Table 1) (14,57). Collectively,
these analyses suggested that LYAR is a component of cer-
tain complexes that mediate rDNA transcription.
UBF is involved in recruitment of LYAR to rDNA
Given that LYAR binds the DNA sequence GGTTAT
through its zinc-finger domain that is similar to the
one found in the globin gene (21), we first examined
whether LYAR interacts directly with rDNA via the
GGTTAT sequence that is located in five different re-
gions of rDNA (GenBank, U13369.1): nucleotides 42992–
42997 (promoter), 3955–3960 (complementary strand, tran-
scribed region), 32632–32637 and 34176–34181 (comple-
mentary strand, intergenic spacer), and 37256–37261 (in-
tergenic spacer). However, the locations of these LYAR-
binding sequences were not consistent with the regions of
rDNA bound to LYAR observed by ChIP analysis; i.e.,
LYAR was not present in intergenic spacer. In fact, an
H0-specific oligonucleotide containing the 42992–42997 se-
quence present in the promoter region did not bind LYAR
as determined with electrophoretic mobility shift assay
(Supplementary Figure S4A). To further examine the in-
volvement, if any, of the LYAR zinc-finger domain in rDNA
binding, we constructed domain mutants of LYAR, in-
cluding ones that lack the N-terminal zinc-finger domain
(LYAR168–379 andLYAR168–260; SupplementaryFigure S4B)
and found that LYAR168–379 could minimally bind rDNA
(Supplementary Figure S4C). Collectively, these data sug-
gested that the zinc-finger domain of LYAR and LYAR-
binding sequences in rDNAare not involved in LYARbind-
ing to rDNA. Because a LYAR mutant lacking the zinc-
finger domain has a dominant-negative effect on the pro-
cessing of pre-rRNAs (20), the zinc-finger domain of LYAR
probably participates in pre-rRNAs processing rather than
rDNA transcription.
We next considered whether LYAR binds rDNA loci via
the basal pre-transcription structural proteins UBF and
treacle (58–67), each of which can associate with LYAR;
this analysis was carried out in concert with knockdown
of UBF, treacle or SPT5 (as a control). We found that
UBF is required for the recruitment of LYAR to regions
H0, H8, and H13 of rDNA as shown by ChIP analysis of
UBF-knockdown cells (Figure 3A), whereas treacle seems
to contribute to the recruitment of LYAR to other regions
in rDNA (H0 and H8) (Supplementary Figure S4D). In ad-
dition, UBF knockdown reduced the localization of LYAR
in the nucleolus and shifted to the nucleolar cap (Figure
3B). Given our previous report that LYAR knockdown did
not alter the nucleolar localization of UBF (20), these data
suggested that LYAR is recruited to rDNA via UBF. We
expected that the knockdown of SPT5 would not affect
LYAR binding to rDNA; however, it significantly increased
LYAR binding to region H0 of rDNA (Figure 3A). This
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
pre-rRNA was biotinylated and then subjected to agarose gel electrophoresis under denaturing condition and northern blotting. Signals for 47/45S pre-
rRNA were detected by chemiluminescence. 18S rRNAs were used as loading controls (stained with methylene blue). The graph shows the relative band
intensities of 2 biotin-labeled 47/45S pre-rRNA normalized to that of 18S rRNA. Data reflect the mean ± SEM of six independent experiments. **P
< 0.01 (paired t-test). (F) prHu3-Luc assay showing the effect of LYAR on RNAP I–dependent transcription. 293T cells were co-transfected with the
prHu3-Luc reporter gene (firefly luciferase) and internal control vector pRL-TK (Renilla luciferase) along with the indicated amount of HBF and/or
HBF-LYAR expression vectors, and luciferase activities were measured. The graph shows the ratio of the luciferase activities (firefly/Renilla) along with
the corresponding HBF-LYAR expression levels or levels of HBF only. Data represent the mean± SEM of three independent experiments. *P< 0.05, **P
< 0.01 (paired t-test). (G) Methylation of rDNA in HBF-LYAR-TO cells was assessed with the HpaII resistance assay. HBF-LYAR-TO cells were treated
with Dox for 24 h and then subjected to HpaII resistance assay. ChIP-CHOP experiment, in which the rDNA promoter-proximal DNA that had been
subjected to ChIP with anti-LYAR or anti-UBF was subjected to HpaII digestion to determine whether LYAR associates with transcriptionally active,
unmethylated rDNA repeats.
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Table 1. LYAR-associating proteins involved or expected to be involved in transcription
Entry name Protein name Gene symbol Gene ID Note
Transcription-FACT complex
SP16H HUMAN FACT complex subunit SPT16 SUPT16H 11198 involved in rDNA transcription
SSRP1 HUMAN FACT complex subunit SSRP1 SSRP1 6749 involved in rDNA transcription
Transcription-DSIF complex
SPT5H HUMAN Transcription elongation factor SPT5 SUPT5H 6829 involved in rDNA transcription
SPT4H HUMAN Transcription elongation factor SPT4 SUPT4H1 6827 involved in rDNA transcription
Transcription-PAF1 complex
RTF1 HUMAN RNA polymerase-associated protein
RTF1 homolog
RTF1 23168 involved in rDNA transcription
CTR9 HUMAN RNA polymerase-associated protein
CTR9 homolog
CTR9 9646 involved in rDNA transcription
LEO1 HUMAN RNA polymerase-associated protein
LEO1
LEO1 123169 involved in rDNA transcription
WDR61 HUMAN WD repeat-containing protein 61 WDR61 80349 involved in rDNA transcription
PAF1 HUMAN RNA polymerase II-associated factor
1 homolog
PAF1 54623 involved in rDNA transcription
Transcription-Super elongation complex (SEC)
AFF4 HUMAN AF4/FMR2 family member 4 AFF4 27125
ENL HUMAN Protein ENL MLLT1 4298
Kinase
CD11B HUMAN Cyclin-dependent kinase 11B CDK11B 984
CSK22 HUMAN Casein kinase II subunit alpha CSNK2A2 1459
CSK2B HUMAN Casein kinase II subunit beta CSNK2B 1460
Topoisomerase & DNA damage
TOP1 HUMAN DNA topoisomerase 1 TOP1 7150 involved in rDNA transcription
DDB1 HUMAN DNA damage-binding protein 1 DDB1 1642
TOP2A HUMAN DNA topoisomerase 2-alpha TOP2A 7153 involved in rDNA transcription
XRCC5 HUMAN X-ray repair cross-complementing
protein 5
XRCC5 7520 involved in rDNA transcription
Transcription-Other
SAFB2 HUMAN Scaffold attachment factor B2 SAFB2 9667
SAFB1 HUMAN Scaffold attachment factor B1 SAFB 6294
BRD4 HUMAN Bromodomain-containing protein 4 BRD4 23476
BRD2 HUMAN Bromodomain-containing protein 2 BRD2 6046
BRD3 HUMAN Bromodomain-containing protein 3 BRD3 8019
CN166 HUMAN UPF0568 protein C14orf166 C14orf166 51637
PELP1 HUMAN Proline-, glutamic acid- and
leucine-rich protein 1
PELP1 27043 involved in rDNA transcription
MATR3 HUMAN Matrin-3 MATR3 9782
RBP56 HUMAN TATA-binding protein-associated
factor 2N
TAF15 8148
T2FA HUMAN General transcription factor IIF
subunit 1
GTF2F1 2962
BCLF1 HUMAN Bcl-2-associated transcription factor 1 BCLAF1 9774
YLPM1 HUMAN YLP motif-containing protein 1 YLPM1 56252
TCOF HUMAN Treacle protein TCOF1 6949 involved in rDNA transcription
IWS1 HUMAN Protein IWS1 homolog IWS1 55677
SPT6H HUMAN Transcription elongation factor SPT6 SUPT6H 6830
MTA1 HUMAN Metastasis-associated protein MTA1 MTA1 9112
SATB2 HUMAN DNA-binding protein SATB2 SATB2 23314
MAX HUMAN Protein max MAX 4149 involved in rDNA transcription
SLTM HUMAN SAFB-like transcription modulator SLTM 79811
TCF20 HUMAN Transcription factor 20 TCF20 6942
ILF3 HUMAN Interleukin enhancer-binding factor 3 ILF3 3609
S30BP HUMAN SAP30-binding protein SAP30BP 29115
increase coincided with the increase of UBF binding to
the H0 region upon SPT5 knockdown (Figure 3A). These
data suggested that LYAR is recruited to rDNA via UBF
and that SPT5 can control LYAR binding to region H0.
On the other hand, the knockdown of UBF or SPT5 re-
duced the binding of LYAR to SPT5 or UBF, respectively
(Figure 3C), suggesting that LYAR can form a complex
with UBF and SPT5. These results could not definitively
determine whether the LYAR-UBF-SPT5 complex forms
upon binding to rDNA or forms prior to binding, i.e. as
a pre-formed unit that might help maintain the equilibrium
among the three protein monomers. Therefore, the mecha-
nism by which UBF and SPT5 regulate LYAR recruitment
to rDNA may be more complicated than previously sus-
pected.
Given that the small molecule CX-5461 inhibits RNAP I
transcription initiation via exclusion of SL1 from the rDNA
promoter and that actinomycin D (actD) inhibits the elon-
gation of rDNA transcription (68,69), we examined the ef-
fects of these compounds on the binding ofUBF and LYAR
to rDNA. Although both compounds inhibited rRNA syn-
thesis (Supplementary Figure S4E), they did not affect the
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Figure 2. Pulldown of LYAR and identification of LYAR-associated pro-
teins (A) Silver staining of HBF-LYAR-associated proteins. HBF-LYAR-
associated complexes were isolated via sequential two-step pulldown (Ni-
NTApulldown,RNaseA treatment, and pulldownofFLAG-taggedHBF-
LYAR) from nuclear extract of HBF-LYAR-TO cells or T-REx 293 cells
(control) treated with Dox for 24 h. Proteins were subjected to SDS-
PAGE and visualized with silver staining. The arrowhead represents HBF-
LYAR, as the bait protein. Molecular mass markers (kDa) are indicated
to the left. Input: nuclear extract (10 g). (B) Immunoblotting of HBF-
LYAR-associated proteins using antibodies indicated to the right of each
panel. 1% Input: 1% of the nuclear extract used for pull down of HBF-
LYAR complexes. HBF-LYAR was detected by Stabilized Streptavidin-
HRP Conjugate.
binding of LYAR to UBF at 6 h treatment (Supplemen-
tary Figure S4E and F), suggesting that these two proteins
form a complex independently of transcription. However,
actD reduced the binding between LYAR and UBF at 2 h
treatment and increased the binding of LYAR to the tran-
scribed region of rDNA but not the promoter or the inter-
genic spacer (Supplementary Figure S4G). Thus, the inhibi-
tion of rDNA transcriptional elongation seems to rearrange
the binding between LYAR and UBF and to trap LYAR on
the transcribed region of rDNA.
LYAR recruits BRD2 to rDNA loci
Given that we identified a number of transcription regula-
tory factors as LYAR-binding proteins (Table 1), we inves-
tigated which transcription regulatory factors have to be re-
cruited to rDNA to increase the transcription of 47S/45S
pre-rRNA via binding to LYAR and looked for transcrip-
tion regulatory factors for which the binding to rDNA
is reduced upon siRNA-mediated knockdown of LYAR.
Among the transcription regulatory factors we examined
(Supplementary Figure S5A), BRD2 exhibited reduced
binding to rDNA (regions H0, H8 and H13) upon LYAR
knockdown, although the overall expression of BRD2 did
not change (Figure 4A). Knockdown of BRD2 itself re-
duced its binding to rDNA, including the region corre-
sponding to H27 (Supplementary Figure S5B), implying
that BRD2 is recruited at a low basal level to rDNA loci
in the absence of LYAR. The binding of LYAR to BRD2
was not affected by the inhibition of RNAP I transcription
with actD or CX-5461 (Supplementary Figure S4F), sug-
gesting that the binding of LYAR to BRD2 is independent
on the RNAP I transcription. By contrast, knockdown of
UBF reduced the binding of BRD2 in regions H0, H18, and
H13 but not H27, as did LYAR (Figure 4A and B). Collec-
tively, these data strongly suggested that LYAR enhances
the recruitment of BRD2 to the promoter and transcribed
regions of rDNA via UBF.
Given our result that the peptide LYAR168–260, which is
rich in lysine residues, could interact with BRD2 (Supple-
mentary Figure S4B), we examined in vitro binding between
LYAR168–260 and each of the recombinant domain mu-
tants of BRD2 (Supplementary Figure S5C). LYAR168–260
could interact with BRD2458–720 or BRD2458–801, each of
which lacks the two canonical bromodomains (Supplemen-
tary Figure S5D). Isothermal titration calorimetry also re-
vealed that peptide BRD2489–540 could interact with pep-
tide LYAR175–219 (Kd = 12.3 M) with 1:1 stoichiome-
try (Supplementary Figure S5E). These results were con-
sistent with recent reports by Luna-Pelaez et al. showing
that the motif B region of BRD2 interacts with the C-
terminal region of LYAR (70). In addition, overexpression
of LYAR increased the binding of BRD2 to rDNA loci
without affecting the overall cellular level of BRD2 (Supple-
mentary Figure S5F). Sequential re-ChIP analysis revealed
co-occupancy of LYAR and BRD2 in rDNA regions H0,
H8 and H13 (Figure 4C), supporting the idea that LYAR
forms a complex with BRD2 via direct interaction and then
the complex associates with rDNA loci via UBF. The fact
that BRD2 overexpression did not affect the binding of
LYAR or UBF to rDNA (Supplementary Figure S5G) ex-
cluded the possibility that BRD2 could increase the binding
of LYARorUBF to rDNA loci. Because BRDproteins had
not previously been shown to be involved in rDNA tran-
scription, we then knocked down BRD2 and found that
47S/45S pre-rRNA synthesis was reduced to the level of
∼60% compared with the mock-knockdown control, as de-
tected by a 30-min incorporation of 4-thiouridine (Figure
4D). Collectively, these data suggested that BRD2 is re-
quired for LYAR-dependent rRNA synthesis.
BRD2 recruits KAT7 to rDNA loci
We further addressed the issue of howBRD2 can upregulate
LYAR-dependent rDNA transcription. Given that BRD2
recruits the histone H4–specific acetyltransferase to the
RNAP II transcription start site (43,71,72), we first exam-
ined whether LYAR-recruited BRD2 could induce acety-
lation of local histones at rDNA loci by using ChIP with
antibodies that recognize acetylated H3 (at K9, K14, K18,
K23 and K27) or acetylated H4 (at K5, K8, K12 and
K16). Similar to the report by Sinha et al. (43), BRD2
knockdown mainly reduced H4 acetylation at rDNA loci
(Figure 5A). Based on our MS-based identification of two
LYAR-associated histone acetyltransferases, namely KAT7
(45) and BRD4 (44) (Table 1 and Supplementary Table
S3), we first examined whether KAT7 is responsible for
the acetylation of histones at rDNA loci. We found that
LYAR overexpression increased the binding of KAT7 to
rDNA, including the intergenic spacer region correspond-
ing to the probe for region H27 (Figure 5B). By contrast,
LYAR knockdown reduced KAT7 binding to rDNA (Fig-
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Figure 3. LYAR recruitment to rDNA loci depends on UBF (A) ChIP analysis of LYAR (left) or UBF binding (right) to rDNA loci in 293T cells upon
knockdown of UBF or SPT5. 293T cells were treated with an siRNA specific for UBF or SPT5 (ncRNA as a control) for 72 h, and whole-cell extract was
subjected to immunoblotting using the antibodies indicated to the right of the panels. -actin was used as the loading control. Molecular mass markers
(kDa) are indicated to the left. The graphs show the amount of ChIPed DNA (% of input) with respect to particular rDNA loci. Data represent the mean
± SEM of three independent experiments. *P < 0.05 (unpaired t-test). (B) Immunocytostaining of LYAR and UBF upon UBF knockdown. 293T cells
were treated with ncRNA or an siRNA specific for UBF for 72 h and subjected to immunocytostaining with anti-LYAR (rabbit) and anti-UBF (mouse).
FITC-conjugated anti-rabbit IgG and Cy3-conjugated anti-mouse IgG were used as the secondary antibodies. DAPI staining indicates the nucleus. Bar:
10 m. (C) Immunoblotting for HBF-LYAR-associated proteins upon siRNA-mediated knockdown of treacle, UBF or SPT5 in HBF-LYAR-TO cells for
72 h. A two-step pulldown was carried out with His6- or FLAG-tag of HBF-LYAR. The antibodies used for immunoblotting are indicated to the right.
ure 5C). These data demonstrated that LYAR has an effect
on KAT7 binding to rDNA beyond the LYAR-binding re-
gion. Moreover, knockdown of BRD2 reduced the amount
of rDNA-associatedKAT7 at regionsH8,H13 anH27 (Fig-
ure 5D). This BRD2 knockdown also reduced the binding
of LYAR to KAT7 and JADE3 that was identified as one
of the LYAR-binding proteins, a possible scaffold partner
of KAT7 (Figure 5E), suggesting that BRD2 bridges be-
tween LYAR andKAT7 (or more likely between LYAR and
KAT7-JADE3). In addition, KAT7 knockdown mainly re-
duced the acetylation of histone H4 at rDNA loci (Figure
5F). Collectively, these data suggested that LYAR recruits
BRD2-KAT7 and possibly JADE3 to acetylate histone H4
within nucleosomes at rDNA loci.
BRD2 assists the recruitment of BRD4 to rDNA loci
We next examined the contribution of another LYAR-
binding acetyltransferase, namely BRD4, to histone acety-
lation at rDNA loci. The overexpression of LYAR in-
creased the binding of BRD4 to rDNA loci without af-
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Figure 4. LYAR recruits BRD2 to rDNA transcription sites (A) ChIP analysis of BRD2 binding to rDNA loci in 293T cells upon LYAR knockdown
(KD). 293T cells were treated with an siRNA specific for LYAR (or ncRNA, control) and then subjected to ChIP analysis with an antibody against LYAR
or BRD2. LYAR KD was confirmed by immunoblotting with antibodies indicated to the right of the panels. -actin was used as the loading control.
Molecular mass markers (kDa) are indicated to the left of the panels. The graphs show the amount of ChIPed DNA (% of input) relative to the number
of rDNA loci with the antibody indicated under each graph. Data represent the mean ± SEM of three independent experiments. *P < 0.05, **P < 0.01
(unpaired t-test). (B) ChIP analysis of BRD2 binding to rDNA loci in 293T cells upon UBF knockdown. The cells were treated with an siRNA specific
for UBF (or ncRNA) and then subjected to ChIP analysis with an antibody against BRD2. The graph shows the amount of ChIPed DNA (% of input).
(C) Re-ChIP analysis showing that LYAR-BRD2-associated complexes bind rDNA loci. The first ChIP of HBF-LYAR, with anti-FLAG, was performed
using HBF-LYAR-TO cells with or without Dox treatment (1st ChIP; left graph). The second ChIP, with anti-BRD2, was performed using the first ChIPed
HBF-LYAR-associated complexes (2nd ChIP; right graph). As an antibody control for anti-BRD2, a nonspecific rabbit IgG was used. The graphs show
the amount of ChIPed DNA (% of input). Data represent the mean± SEM of three independent experiments. *P< 0.05, **P< 0.01 (unpaired t-test). (D)
Metabolic labeling (4-thiouridine) of newly synthesized 47/45S pre-rRNA in 293T cells upon BRD2 knockdown (siRNA). The pre-rRNAwas biotinylated
and then subjected to agarose gel electrophoresis under denaturing condition and northern blotting. The signals for 47/45S pre-rRNA were detected by
chemiluminescence. 28S and 18S rRNAs were used as loading controls (stained with SYBR gold). The graph shows the relative band intensities of biotin-
labeled 47/45S pre-rRNA normalized to that of 18S rRNA. Data represent the mean ± SEM of four independent experiments. *P < 0.05, **P < 0.01
(paired t-test). Knockdown of BRD2 was confirmed by immunoblotting with anti-BRD2. -actin was used as the loading control.
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Figure 5. BRD2 recruits KAT7 to rDNA loci (A) ChIP analysis of the extent to whichH3 orH4 is acetylated. 293T cells were treated with an siRNA specific
for BRD2 or ncRNA (control) and then subjected to ChIP analysis with an antibody against H3ac or H4ac, as indicated. The graphs show the amount
of ChIPed DNA (% of input) relative to the number of rDNA loci indicated under each graph. Data represent the mean ± SEM of three independent
experiments. *P < 0.05, **P < 0.01 (unpaired t-test). B–D) ChIP analysis of the binding of KAT7 to rDNA loci. HBF-LYAR-TO cells were treated with
(+Dox) or without (–Dox) Dox (B). 293T cells were treated with ncRNA (control) or an siRNA specific for LYAR (C) or BRD2 (D) for 72 h. These cells
were subjected to ChIP analysis with an antibody against KAT7. The graphs show the amount of ChIPed DNA (% of input) relative to the number of
rDNA loci indicated under each graph. Data represent the mean ± SEM of three independent experiments. *P < 0.05, **P < 0.01 (unpaired t-test). (E)
Immunoblotting for HBF-LYAR-associated proteins upon the knockdown of BRD2. HBF-LYAR-TO cells were treated with an siRNA specific for BRD2
for 72 h; after induction with Dox, the nuclear extract was subjected to the pulldown with two-step pull down with His6- and FLAG-tag of HBF-LYAR.
HBF-LYAR-associated proteins were detected by immunoblotting with antibodies indicated to the right of the panels. (F) ChIP analysis of the extent to
which H3 or H4 is acetylated. 293T cells were treated with an siRNA specific for KAT7. These cells were subjected to ChIP analysis with an antibody
against H3ac or H4ac, as indicated. 293T cells were treated with ncRNA (control) or an siRNA specific for KAT7. The graphs show the amount of ChIPed
DNA (% of input) relative to the number of rDNA loci indicated under each graph. Data represent the mean ± SEM of three independent experiments.
*P < 0.05, **P < 0.01 (unpaired t-test).
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fecting the overall expression level of BRD4 (Supplemen-
tary Figure S5F). In addition, the knockdown of LYAR
or BRD2 reduced the binding of BRD4 to rDNA (Fig-
ure 6A and B); as expected, knockdown of BRD4 reduced
its own association with rDNA loci (Supplementary Fig-
ure S6A). BRD4 knockdown reduced the acetylation of
both histones H3 and H4 at rDNA loci, except for region
H27 (Figure 6C).Moreover, LYARknockdown reduced the
overall acetylation of both H3 and H4 at the rDNA pro-
moter as well as the transcribed and intergenic spacer re-
gions of rDNA loci (Figure 6D), whereas LYAR overex-
pression increased the overall acetylation of both H3 and
H4 (Figure 6E). Given that BRD4 catalyzes the acetylation
of H3K122 (H3acK122), which is sufficient to stimulate
transcription of rDNA (73), we also tested whether acetyla-
tion at H3K122 is increased by overexpression of LYAR via
the ability to recruit BRD4 to rDNA. ChIP analysis with
anti-H3acK122 revealed that LYAR overexpression caused
a significant increase in H3acK122 at rDNA loci including
region H27 (Figure 6F), suggesting that LYAR-recruited
BRD4 is also responsible for H3K122 acetylation at rDNA
loci. Consistent with these data, BRD4 knockdown reduced
47S/45S pre-rRNA synthesis to ∼35% compared with the
mock-knockdown control, as detected by a 30-min incor-
poration of 4-thiouridine (Figure 6G). However, the his-
tone acetyltransferases GCN5 and p300 were not identi-
fied as LYAR-associated proteins (Supplementary Tables
S3 and S4), and indeed LYAR did not affect the binding
of either GCN5 or p300 to rDNA (Supplementary Figure
S6B) (11,74). Collectively, these data suggested that LYAR-
mediated recruitment of BRD2,KAT7 andBRD4 to rDNA
controls the acetylation of local histones H3 and H4 to
cause the relaxation of these histones from rDNA loci and
thereby promote rDNA transcription.
BRD2 and BRD4 form complexes with LYAR and KAT7-
JADE3 independently of each other
To examine the relationship among complexes formed by
LYAR, UBF, BRD2/4, KAT7-JADE3 and SPT5, we car-
ried out a reverse pulldown assay using each of those pro-
teins, individually, as the affinity bait. We initially per-
formed a two-step pulldown using HBF-LYAR as the first
affinity bait and endogenous SPT5 or UBF as the sec-
ond affinity bait. Although LYAR-UBF could associate
with BRD2 or BRD4 even at basal cellular levels (Fig-
ure 7A), LYAR-SPT5 did not associate with BRD2 or
BRD4 at all (Figure 7B). Conversely, a pulldown assay
using BRD2 or BRD4 as bait showed that neither pro-
tein could associate with SPT5 or UBF; however, BRD2
and BRD4––independently of each other––could form a
complex containing both LYAR and KAT7-JADE3 (Fig-
ure 7C). In addition, knockdown of BRD2 did not affect
the binding of BRD4 to LYAR, and vice versa (Figures 5E
and 7D). Collectively, these data support the previous no-
tice that LYAR forms a complex with BRD2 or BRD4, after
which either complex can be recruited to rDNA via UBF.
Furthermore, the association of LYAR with KAT7-JADE3
is dependent on BRD2 (Figure 5E) but not on BRD4 (Fig-
ure 7D), suggesting that BRD2 and BRD4 differentially
promote the recruitment of KAT7-JADE3 to rDNA.
DISCUSSION
Our results demonstrate that LYAR has a role in rDNA
transcription. Given that LYAR overexpression does not
affect the cellular levels of MYC, PTEN, retinoblastoma,
and p53 (20), we hypothesized that LYAR promotes rDNA
transcription via a pathway independent of those proteins,
although we could not exclude the possibility that LYAR-
induced proteins other than those listed above may be in-
volved in rDNA transcription. Among several transcrip-
tion regulatory factors that associate with LYAR (Table
1), we identified BRD2, KAT7, and BRD4 as being re-
cruited by LYAR to rDNA. Although BET family pro-
teins and MYST-type acetyltransferases are essential me-
diators of RNAP II–dependent transcription (75,76), their
involvement in RNAP I–dependent transcription is un-
known. Thus, to our knowledge, this is the first report that
provides evidence of a role for BRD proteins and KAT7 in
RNAP I–dependent transcription.
BRD2 associates with the RNAP II mediator complex
containing E2F-TATA-box–binding proteins that is pro-
posed to recruit histone acetyltransferases to DNA during
RNAP II–dependent transcription (71). However, it is less
likely that LYAR recruits the E2F-TATA-box transcription
factors to rDNA via its association with BRD2 because
our MS-based analysis did not identify any of the proteins
known to associate with BRD2 (Table 1). Instead of those
proteins, we found that BRD2 assists the recruitment of
KAT7 and BRD4 to rDNA. Based on our present findings,
we propose a mechanism for LYAR-mediated enhancement
of rDNA transcription (Figure 8). First, upon its increased
expression, LYAR forms a complex with BRD2-KAT7 (or
BRD4-KAT7); the complex probably contains JADE3. Sec-
ond, LYAR-BRD2-KAT7 complex binds to the promoter
and transcribed regions of rDNA loci via UBF. Third,
KAT7 acetylates histone H4 in nucleosomes at rDNA. Al-
ternatively, LYAR may recruit BRD4-KAT7 to rDNA loci
regardless of whether BRD2 is already present at those loci
to accelerate BRD4-KAT7 binding to acetylated H4. Fi-
nally, BRD4-KAT7 assists the acetylation of both H4 and
H3 near the LYAR-binding site on rDNA and promotes
BRD4-KAT7 binding to rDNA loci to relax the nucleo-
some structure, which enhances RNAP I–mediated tran-
scription (Figure 8). In this mechanism, LYAR binds di-
rectly to BRD2 and recruits it to rDNA loci without in-
volvement of acetylated histones. This is in contrast to the
involvement of BRD2 in RNAP II–dependent transcrip-
tion, in which it is recruited to an acetylated histone (e.g.,
H4K12ac) (77). By contrast, an unknown protein(s) may be
required for the binding of LYAR to BRD4. This proposed
mechanismmay explain why BRD4 is recruited to the inter-
genic spacer encompassing H27 beyond regionH13 (Figure
6A). A similar function of theMYST-type acetyltransferase
has been reported to facilitate HIV (human immunodefi-
ciency virus) latency in human cells; in that case, BRD4 is
recruited to the HIV long, terminal repeat by interacting
with acetylated H4 (acetylation catalyzed by KAT5) (78).
One issue this mechanism does not address is whether
the intrinsic histone acetylase activity of BRD4 is respon-
sible for LYAR-induced acetylation of histones H3 and H4
or whether BRD4 recruits a different acetyltransferase. The
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Figure 6. LYAR and BRD2 assist the recruitment of BRD4 to rDNA (A, B) ChIP analysis of the binding of BRD4 to rDNA upon the knockdown of
LYAR (A) or BRD2 (B). 293T cells were treated with ncRNA or an siRNA specific for LYAR (A) or BRD2 (B) for 72 h. These cells were subjected to
ChIP analysis with an antibody against BRD4. The graphs show the amount of ChIPed DNA (% of input) relative to the number of rDNA loci indicated
under each graph. Data represent the mean ± SEM of three independent experiments. *P < 0.05, **P < 0.01 (unpaired t-test). (C, D) ChIP analysis of
the extent to which H3 or H4 is acetylated in 293T cells. The cells were treated with ncRNA or an siRNA specific for BRD4 (C) or LYAR (D) for 72 h.
These cells were subjected to ChIP analysis with an antibody against H3ac or H4ac, as indicated. (E, F) ChIP analysis of the extent to which H3 or H4
is acetylated in HBF-LYAR-TO cells. The cells were treated with (Dox+) or without Dox (Dox–) for 24 h. These cells were subjected to ChIP analysis
with an antibody against H3ac or H4ac (E), or H3K122ac (F). (G) Metabolic labeling (4-thiouridine) of newly synthesized 47/45S pre-rRNA in 293T
cells upon BRD4 knockdown (siRNA) for 72 h. The pre-rRNA was biotinylated and then subjected to agarose gel electrophoresis and northern blotting.
The signals for 47/45S pre-rRNA were detected by chemiluminescence. 28S and 18S rRNAs were used as loading controls (stained with SYBR gold). The
graph shows the relative band intensities of biotin-labeled 47/45S pre-rRNA normalized to that of 18S rRNA. Data represent the mean ± SEM of four
independent experiments. *P < 0.05, **P < 0.01 (paired t-test). Knockdown of BRD4 was confirmed by immunoblotting with anti-BRD4. -actin was
used as the loading control.
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Figure 7. BRD2, BRD4, and SPT5 bind LYAR independently (A, B) Re-
verse pulldown (PD) ofUBF (A) or SPT5 (B) fromHBF-LYARcomplexes,
assessed with immunoblotting. HBF-LYAR-TO cells were treated with
Dox for 24 h, and then nuclear extracts (NE) were subjected to first pull-
down (first PD) by two-step immunoprecipitation using His6- and FLAG-
tag of HBF-LYAR. The purified HBF-LYAR complexes were immuno-
precipitated with anti-UBF (UBF) (A) or anti-SPT5 (SPT5) (B) as the
second affinity bait (second PD). T-REx 293 cells treated with Dox were
used as the control. Proteins were detected by immunoblotting using the
antibodies indicated to the right of the panels. Molecular mass markers
(kDa) are indicated to the left of the panels. The nuclear extract (NE, 10
g) was used as a loading control. (C) Immunoblotting for proteins that
associatedwithBRD2orBRD4.HBF-BRD2-TOcells andFLAG-BRD4-
TO cells were treated with Dox for 24 h, and then the nuclear extracts were
subjected to a two-step immunoprecipitation (IP) with anti-His6 and anti-
FLAG. T-REx 293 cells treated with Dox were used as the control. Pro-
teins that associated with HBF-BRD2 or FLAG-BRD4 were detected by
immunoblotting using the antibodies indicated to the right of the panels.
-actin was used as the loading control. (D) Immunoblotting for HBF-
LYAR-associated proteins upon the knockdown of BRD4. HBF-LYAR-
TO cells were treated with an siRNA specific for BRD4 for 72 h. After
induction with Dox, the nuclear extracts were subjected to two-step im-
munoprecipitation (IP) using His6- and FLAG-tag of HBF-LYAR.
lysine residues in H3 and H4 that are acetylated by BRD4
are distinct from those of other histone acetyltransferases,
especially the acetylation of K122 in H3 (H3K112ac) (44).
Given that overexpression of LYAR increased the frequency
of H3acK122 (Figure 6F), it is likely that the intrinsic
acetylase activity of BRD4 is involved in acetylation as-
sisted by LYAR on rDNA loci. Although two other acetyl-
transferases, namely P300/CBP (79) and SIRT7 (80), can
generate H3K122ac, we did not identify those acetyltrans-
ferases as LYAR-associated proteins, supporting the afore-
mentioned hypothesis that the intrinsic histone acetylase
activity of BRD4 is responsible for LYAR-induced acety-
Figure 8. Model for LYAR function in rDNA transcription For RNAP
I–dependent transcription, LYAR binds rDNA via UBF, recruits BRD2-
KAT7-JADE3 through direct binding between LYAR and BRD2 (without
any auxiliary factor) to rDNA transcription sites, and accelerates acety-
lation of histone H4. Moreover, LYAR facilitates the binding of BRD4-
KAT7-JADE3 to acetylated H4 at rDNA transcription sites. BRD4-
KAT7-JADE3 further accelerates the acetylation of histones H3 and
H4 at rDNA loci, which further enhances BRD4-KAT7-JADE3 binding
to rDNA loci, resulting in the relaxation of chromatin structure to en-
hance RNAP I–dependent transcription. Because the binding of LYAR
to KAT7-JADE3 is dependent on BRD2 but not BRD4, an unknown fac-
tor may be involved in the binding between LYAR and KAT7-JADE3 in
the LYAR-BRD4-KAT7-JADE3 complex.
lation. However, it is possible that other unknown acetyl-
transferases are involved in LYAR-assisted histone acetyla-
tion at rDNA loci.
Another issue with this mechanism is whether LYAR
binds rDNA directly or indirectly. Our data show that
LYAR binds rDNA indirectly via binding to UBF, and
we serendipitously found that SPT5 regulates UBF bind-
ing to the rDNA promoter, and thus SPT5 probably reg-
ulates LYAR binding to that promoter. In addition, we
demonstrated that SPT5-UBF and BRD2-KAT7-JADE3
(or BRD4-KAT7-JADE3) form complexes with LYAR in-
dependently of each other (Figure 7A–C). Given that UBF
and SPT5 participate in the pause and release, respectively,
of RNAP I from the rDNA promoter (35,54,81), the initi-
ation of rDNA transcription can be regulated by a similar
mechanism, i.e., RNAP I is initially paused at the promoter
but is released upon LYAR-BRD2-KAT7-JADE3 binding
to UBF. This RNAP I release mechanism is consistent with
our result that LYAR affected neither the binding of two
RNAP I subunits, RPA194 and RPA135, to rDNA (Sup-
plementary Figure S5A) nor the state of DNA methylation
(Supplementary Figure S2F). However, LYAR overexpres-
sion did not alter the binding of SPT5 to rDNA loci, in-
cluding the promoter (Supplementary Figure S5A). Thus,
we propose that LYAR binding to rDNA is not involved in
the release of paused RNAP I from the promoter, although
we cannot exclude the possibility that LYAR binding alters
the association between SPT5 andUBF via histone acetyla-
tion by KAT7/BRD4 at the rDNA promoter or phospho-
rylation of UBF via the kinase activity of BRD2.
Based on our current results and those of our previous
study (20), we propose that upregulation of LYAR in cer-
tain cancer cells promotes rDNA transcription and pre-
rRNA processing, resulting in increased ribosome biogen-
esis and maintenance of rapid growth and proliferation.
Therefore, it will be interesting to determine whether can-
cer cells that expressLYAR at a high level canmaintain their
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tumorigenic potential upon suppression of LYAR function
in rRNA synthesis. Recent research revealed that the cell-
permeable molecule JQ1 inhibits the binding of BRD pro-
teins with acetylated histones and is a potential therapeutic
agent for the treatment of acute myeloid leukemia (82,83).
Our present findings concerning the potential interactions
among LYAR/UBF, LYAR/BRD2-KAT7-JADE3 and/or
LYAR/BRD4-KAT7-JADE3 may provide other potential
targets for cancer treatment.
Finally, it has been shown that the modulation of rRNA
synthesis is closely linked to cell differentiation of ovarian
germline stem cells in Drosophila (35) and in human cells
with differentiation potential, including embryonic stem
cells (34) and promyelocytic and monocytic leukemia cells
(84). Therefore, it is likely that LYARmaintains the pluripo-
tency of embryonic stem cells by promoting rRNA synthe-
sis. It is also possible that the physiological convergence of
BRD2 and BRD4 observed in early embryogenesis in mice
(85,86) may be a consequence of their roles––as mediated
by LYAR––in rRNA synthesis.
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